Stock Research for ARWR


Featured Broker: Ally Invest

Get the due diligence for another stock.


ARWR Stock Chart & Research Data

The ARWR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARWR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ARWR Due diligence Resources & Stock Charts

The ARWR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARWR Detailed Price Forecast - CNN Money CNN View ARWR Detailed Summary - Google Finance
Yahoo View ARWR Detailed Summary - Yahoo! Finance Zacks View ARWR Stock Research & Analysis -

Stock Analysis

TradeIdeas View ARWR Trends & Analysis - Trade-Ideas Barrons View ARWR Major Holders - Barrons
NASDAQ View ARWR Call Transcripts - NASDAQ Seeking View ARWR Breaking News & Analysis - Seeking Alpha
Spotlight View ARWR Annual Report - OTC Report View ARWR OTC Short Report -
TradeKing View ARWR Fundamentals - TradeKing Charts View ARWR SEC Filings - Bar Chart
WSJ View Historical Prices for ARWR - The WSJ Morningstar View Performance/Total Return for ARWR - Morningstar
MarketWatch View the Analyst Estimates for ARWR - MarketWatch CNBC View the Earnings History for ARWR - CNBC
StockMarketWatch View the ARWR Earnings - StockMarketWatch MacroAxis View ARWR Buy or Sell Recommendations - MacroAxis
Bullish View the ARWR Bullish Patterns - American Bulls Short Pains View ARWR Short Pain Metrics -

Social Media Mentions

StockTwits View ARWR Stock Mentions - StockTwits PennyStocks View ARWR Stock Mentions - PennyStockTweets
Twitter View ARWR Stock Mentions - Twitter Invest Hub View ARWR Investment Forum News - Investor Hub
Yahoo View ARWR Stock Mentions - Yahoo! Message Board Seeking Alpha View ARWR Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ARWR - Insider Cow View Insider Transactions for ARWR - Insider Cow
CNBC View ARWR Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARWR - OTC Markets
Yahoo View Insider Transactions for ARWR - Yahoo! Finance NASDAQ View Institutional Holdings for ARWR - NASDAQ

Stock Charts

FinViz View ARWR Stock Insight & Charts - StockCharts View ARWR Investment Charts -
BarChart View ARWR Stock Overview & Charts - BarChart Trading View View ARWR User Generated Charts - Trading View

Latest Financial News for ARWR

Today’s Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals
Posted on Monday May 21, 2018

NEW YORK, NY / ACCESSWIRE / May 21, 2018 / Agile Therapeutics shares fell hard on Friday after traders pondered the future of the company's Twirla contraceptive Patch. The FDA had a concerning assessment on the patch and has already turned it down twice. Shares of Arrowhead Pharmaceuticals were gaining higher in Friday trading despite any particular news.

Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
Posted on Monday May 21, 2018

Arrowhead Pharmaceuticals, Inc. (ARWR) today announced the presentation of new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, for the treatment of cystic fibrosis (CF), at the American Thoracic Society (ATS) 2018 International Conference in San Diego, CA. ARO-ENaC is the first product candidate to leverage the Targeted RNAi Molecule (TRiM™) platform targeting the pulmonary epithelium to address diseases of the lung. ARO-ENaC is an inhaled RNA interference (RNAi) therapeutic targeting the epithelial sodium channel alpha subunit (αENaC) for the treatment of CF, a rare disease caused by a genetic mutation that leads to mucus buildup in the lungs and pancreas.

Edited Transcript of ARWR earnings conference call or presentation 8-May-18 8:30pm GMT
Posted on Tuesday May 15, 2018

Q2 2018 Arrowhead Pharmaceuticals Inc Earnings Call

Wired News – Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases
Posted on Tuesday May 15, 2018

LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Arrowhead Pharma, Inc. (NASDAQ: ARWR), all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it presented new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3 and ARO-APOC3 at the Vascular Discovery: From Genes to Medicine– Scientific Sessions 2018, San Francisco, May 10-12, 2018, a symposium organized by the American Heart Association. Arrowhead intends to file clinical trial applications (CTA) for ARO-ANG3 and ARO-APOC3 before the end of 2018.

Enter a stock symbol to view the stock details.